These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 14616732

  • 21. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
    Stefani S, Castiglia P, Maida A, Muresu E, Mezzatesta ML, Nicoletti G.
    J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
    [Abstract] [Full Text] [Related]

  • 22. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group.
    Murray PR, Cantrell HF, Lankford RB.
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):111-20. PubMed ID: 7805355
    [Abstract] [Full Text] [Related]

  • 23. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.
    Baron EJ, Jones RN.
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):141-51. PubMed ID: 7648835
    [Abstract] [Full Text] [Related]

  • 24. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, Roussel-Delvallez M.
    BMC Infect Dis; 2010 Mar 18; 10():72. PubMed ID: 20298555
    [Abstract] [Full Text] [Related]

  • 25. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN, Barry AL.
    Diagn Microbiol Infect Dis; 1989 Mar 18; 12(6):495-510. PubMed ID: 2560422
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
    Higashitani F, Hyodo A, Ishida N, Inoue M, Mitsuhashi S.
    J Antimicrob Chemother; 1990 Apr 18; 25(4):567-74. PubMed ID: 2161820
    [Abstract] [Full Text] [Related]

  • 27. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
    Cormican M, Corbett-Feeney G, Kelly S, Hughes D, Flynn J, Jones RN.
    Ir J Med Sci; 1998 Apr 18; 167(3):155-9. PubMed ID: 9780564
    [Abstract] [Full Text] [Related]

  • 28. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
    Chen HY, Bonfiglio G, Allen M, Piper D, Edwardson T, McVey D, Livermore DM.
    J Antimicrob Chemother; 1993 Aug 18; 32(2):247-66. PubMed ID: 8226427
    [Abstract] [Full Text] [Related]

  • 29. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC.
    J Antimicrob Chemother; 1993 Jan 18; 31 Suppl A():29-38. PubMed ID: 8383654
    [Abstract] [Full Text] [Related]

  • 30. In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data.
    Hung MN, Hsueh PR, Chang HT, Lee WS, Chou MY, Chen IS, Wang JH, Lin CF, Shyr JM, Ko WC, Wu JJ, Liu YC, Huang WK, Teng LJ, Liu CY, Luh KT.
    Int J Antimicrob Agents; 2007 Feb 18; 29(2):145-52. PubMed ID: 16815690
    [Abstract] [Full Text] [Related]

  • 31. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Int J Antimicrob Agents; 2014 Jun 18; 43(6):533-9. PubMed ID: 24856078
    [Abstract] [Full Text] [Related]

  • 32. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C, Xie W, Zhang W, Ye Z, Wu H.
    Zhonghua Shao Shang Za Zhi; 2014 Apr 18; 30(2):166-70. PubMed ID: 24989663
    [Abstract] [Full Text] [Related]

  • 33. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
    Anuradha K, Sailaja VV, Umabala P, Satheesh T, Lakshmi V.
    Indian J Med Microbiol; 2007 Jul 18; 25(3):203-8. PubMed ID: 17901635
    [Abstract] [Full Text] [Related]

  • 34. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD.
    Pharmacotherapy; 2000 Sep 18; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [Abstract] [Full Text] [Related]

  • 35. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF, Wildfeuer A.
    Arzneimittelforschung; 1990 Oct 18; 40(10):1145-55. PubMed ID: 2291754
    [Abstract] [Full Text] [Related]

  • 36. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
    Livermore DM, Mushtaq S, James D, Potz N, Walker RA, Charlett A, Warburton F, Johnson AP, Warner M, Henwood CJ.
    Int J Antimicrob Agents; 2003 Jul 18; 22(1):14-27. PubMed ID: 12842324
    [Abstract] [Full Text] [Related]

  • 37. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL, Occhipinti DJ, Rodvold KA, Danziger LH.
    Ann Pharmacother; 1995 May 18; 29(5):501-14. PubMed ID: 7655135
    [Abstract] [Full Text] [Related]

  • 38. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
    Varotto F, Maria GD, Azzaro R, Bellissima P, Amato R, Fogliani V, Muscianisi G, Vitale S, Girbino G, Andò F, Laganà P, Delia S, Jacoviello C, Maierna G, Pezza A, Covelli I, Magrì M, Napoletano G, Rossi A, Marone P, Sanguinetti C, Pela R, Tedeschi D, Viola B, Cicciarella S, Messina G, Rizza S, Fraschini F.
    J Chemother; 2001 Aug 18; 13(4):413-23. PubMed ID: 11589485
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.